Summit Therapeutics, Inc. (SMMT)
13.33
+0.28
(+2.15%)
USD |
NASDAQ |
Jun 11, 11:05
Summit Therapeutics Accounts Payable (Quarterly) : 27.55M for March 31, 2026
Accounts Payable (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Accounts Payable (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 27.55M |
| December 31, 2025 | 20.29M |
| September 30, 2025 | 22.24M |
| June 30, 2025 | 22.98M |
| March 31, 2025 | 4.994M |
| December 31, 2024 | 4.636M |
| September 30, 2024 | 3.252M |
| June 30, 2024 | 3.34M |
| March 31, 2024 | 6.371M |
| December 31, 2023 | 2.667M |
| September 30, 2023 | 3.314M |
| June 30, 2023 | 0.987M |
| March 31, 2023 | 0.71M |
| December 31, 2022 | 0.355M |
| September 30, 2022 | 1.431M |
| June 30, 2022 | 3.574M |
| March 31, 2022 | 6.959M |
| December 31, 2021 | 4.374M |
| September 30, 2021 | 5.875M |
| June 30, 2021 | 6.949M |
| March 31, 2021 | 4.114M |
| December 31, 2020 | 6.14M |
| September 30, 2020 | 2.493M |
| Date | Value |
|---|---|
| June 30, 2020 | |
| March 31, 2020 | 12.59M |
| January 31, 2020 | |
| October 31, 2019 | |
| July 31, 2019 | |
| April 30, 2019 | |
| January 31, 2019 | 11.66M |
| October 31, 2018 | 6.787M |
| July 31, 2018 | 8.639M |
| April 30, 2018 | 12.03M |
| January 31, 2018 | 12.70M |
| October 31, 2017 | 5.200M |
| July 31, 2017 | 4.627M |
| April 30, 2017 | 4.130M |
| January 31, 2017 | 5.012M |
| October 31, 2016 | 3.856M |
| July 31, 2016 | 4.397M |
| April 30, 2016 | 4.582M |
| January 31, 2016 | 1.016M |
| October 31, 2015 | 4.323M |
| July 31, 2015 | 4.156M |
| April 30, 2015 | 4.16M |
| January 31, 2015 | 1.795M |
Accounts Payable Definition
Accounting terminology for money that a company owes to vendors for services or products that it purchased on credit. Accounts payable appear on the balance sheet as a current liability.
Accounts Payable (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Accounts Payable (Quarterly) Benchmarks
| Revolution Medicines, Inc. | 80.54M |
| Denali Therapeutics, Inc. | 40.38M |
| NovelStem International Corp. | 0.00 |
| Brainstorm Cell Therapeutics, Inc. | 7.317M |
| Kezar Life Sciences, Inc. | 0.273M |